Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 ...
The current Bundibugyo Ebola virus (BDBV) outbreak in the Democratic Republic of the Congo is the second largest Ebola ...
Vir Biotechnology, entered a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN dual-masked T-cell engager development candidates target ...
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development ...
The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation ...
Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and ...
FDA Clears First-in-Human CLEC2A-Directed CAR T-Cell Trial / AML, cancer care, Cancer research, CAR T-CELL, Danielle Kirkey, ...
Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; ...
October 12, 2026) - Frost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically ...
A longitudinal study finds that older adults who recovered from COVID-19 mount weakened non-spike-specific Th1 CD4+ T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results